Attomarker Seed
2 known investors
Find your way into Attomarker Seed
507 people in our graph share verified history with the Attomarker Seed team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Andrew Shaw · together at Stanford University (overlapped)
.jpeg)
×9knows the team · via Stanford University
×2knows the team · via University of Southampton
Attomarker develops a multiplexed blood testing platform that measures multiple biomarkers simultaneously and quantitatively, using gold particle nanotechnology, microfluidics and data analytics. Its tests, including a COVID Antibody Spectrum Test that classifies Long COVID immune endotypes, serve patients, clinicians, researchers and clinical partners for precision diagnostics and personalised medicine.
Founders & leadership
AS
Andrew ShawinCEO and FounderAndrew Shaw studied quantum mechanics and spent two years at Stanford before founding EvanesCo, a company focused on counter-terrorism and weapons detection; he later sold a rheumatoid arthritis company and went on to develop biomarker detection technology as a research grant recipient at the University of Exeter, which became the core intellectual property for Attomarker.
Investors · 2
Frequently asked questions
- What does Attomarker Seed do?
- Attomarker develops a multiplexed blood testing platform that measures multiple biomarkers simultaneously and quantitatively, using gold particle nanotechnology, microfluidics and data analytics. Its tests, including a COVID Antibody Spectrum Test that classifies Long COVID immune endotypes, serve patients, clinicians, researchers and clinical partners for precision diagnostics and personalised medicine.
- Who founded Attomarker Seed?
- Attomarker Seed was founded by Andrew Shaw.
- Who are Attomarker Seed's investors?
- Attomarker Seed's investors include Future Planet Capital, Milltrust International Group.